During that decade, naxitamab, the humanized version of m3F8 (hu3F8), received FDA breakthrough designation in 2018 and final approval in 2020 in combination with GM-CSF for pediatric and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow if there is a partial response, minor response, or stable disease to standard induction therapy [51]. Here, CSF2 is linked to neuroblastoma.